본문 바로가기
bar_progress

Text Size

Close

Treatment Released! "All-Time Best" Bio Stocks Are About to Explode!

Congratulations to those who applied for the free trial and sold at the upper limit price of ‘Jungang Enervis (000440)’!

*For those who applied late, don’t worry, there will be another chance.

*Finally starting! Explosive performance by pioneering a new market worth 10 times the existing market! Upper limit price on Thursday.*


In a project worth a whopping 300 trillion KRW, surpassing renowned large corporations,

the first confirmed domestic deployment triggers an order explosion worth 10 times the market capitalization!


Foreign and institutional investors are accumulating shares?this company is no ordinary case.

The opportunity is only for today! The stock price will surge immediately at tomorrow’s opening?what’s 30%?

You should at least aim for 10 times, 300%!


▶▶ SK Bioscience follow-up! A top-tier leading stock boasting 400% returns!! Get the info now for free => [Click]


‘o o o’ COVID-19 oral treatment Phase 2 clinical trial approved! + Global clinical trials underway simultaneously!

A perfect ‘o o o’ treatment with no side effects! Explosive inquiries from global major pharmaceutical companies!

Global clinical trial agency One PICK!! Fastest development ever completed! Export imminent upon result announcement!

About 10 billion times more effective than existing methods, accelerating domestic company supply volume!!


▶▶ Materials that will trigger an immediate 'upper limit price' upon disclosure, related industries soaring with steel scrap dual rally! ▶ Apply for free trial ◀▶▶ "Thursday" heads straight to the top. Don’t miss the leading stock! [Apply now for free upper limit price]


There is no second chance. You must seize the opportunity when it comes.

It will explode exactly on "September 23"! Don’t miss it and buy at least 100,000 KRW worth!


So, which stocks do you recommend?


▶▶ "September 23 Upper Limit Price" will be provided only until today and then closed. [Get it now!]


*Free trial reviews*

"I couldn’t believe my own eyes. My stock account return rate was 100%...

I agonized hundreds of times before joining, but it was really all unnecessary.

This is my result after one week, but those who used it longer probably exceeded 1,000% returns.

Thank you so much! I’m really looking forward to the next recommended stock!!!!"

(Office worker Lee Ji-yeon, 33 years old)


[Recent upper limit price hits]

*21.09.10 Amosense (357580) upper limit hit!

*21.09.03 Phoenix Materials (050090) upper limit hit!

*21.08.24 Aztec WB (032080) upper limit hit!

*21.08.19 Younghwa Tech (265560) upper limit hit!

*21.08.09 EcoPro (086520) upper limit hit!

*21.08.04 Koses (089890) upper limit hit!

*21.07.30 Gaon Media (078890) upper limit hit!

*21.07.26 Woongjin (016880) upper limit hit!

*21.07.21 A-Root (096690) upper limit hit!

*21.07.19 Shinil Electronics (002700) upper limit hit!

*21.07.13 Bukuk Steel (026940) upper limit hit!

*21.07.05 Korea BNC (256840) upper limit hit!

*21.07.01 Ilseong Construction (013360) upper limit hit!

*21.06.28 PHC (057880) upper limit hit!

*21.06.23 Solgo Bio (043100) upper limit hit!

*21.06.15 WISCOM (024070) upper limit hit!

*21.06.07 BHI (083650) upper limit hit!

*21.06.04 SGA Solutions (184230) upper limit hit!

*21.05.31 Sambo Industry (009620) upper limit hit!

*21.05.25 Ilyeon Pharmaceutical (102460) upper limit hit!

*21.05.20 Daeduck (008060) upper limit hit!

*21.05.14 Igen (185490) 2nd upper limit hit!

*21.04.25 Next Science (003580) 2nd upper limit hit!

*21.04.13 IOK (078860) 2nd upper limit hit!

*21.04.05 Humasis (205470) upper limit hit!


*Limited to first 30 applicants! Recruiting the hero of a bases-loaded home run with two outs in the 9th inning*


[Today’s stocks of interest]

SK Bioscience SL Bionics Korea BNC Nano CMS Aprogen Pharmaceutical


※ This content is unrelated to the editorial direction of Asia Economy, and all responsibility lies with the information provider.


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top